Designation of Propranolol Hydrochloride as an Orphan Drug - Pierre Fabre Medicament Australia Pty Limited

Administered by Department of Health, Disability and Ageing

Legislation au C2012G00073 In force Gazette

Legislation content

DESIGNATION OF Propranolol Hydrochloride AS AN ORPHAN DRUG

 

I, Dr Anthony Gill, Delegate of the Secretary for the purposes of 16J of the Therapeutic Goods Regulations 1990 (“the Regulations”), acting under subregulation 16J (2) of the Regulations, designate Propranolol Hydrochloride as an orphan drug on the 3rd October 2012 for the treatment of proliferating infantile hemangiomas requiring systemic therapy.

 

 

The dose form of Propranolol Hydrochloride for this indication is oral solution.

 

 

The sponsor of Propranolol Hydrochloride is Pierre Fabre Medicament Australia Pty Limited.

 

 

 

 

 

 

 

(signed by)

 

Dr Anthony Gill

Delegate of the Secretary

 

3rd October 2012

 

 

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.